Gadolinium-enhanced magnetic resonance imaging for renovascular disease and nephrogenic systemic fibrosis: critical review of the literature and uk experience

Journal of Magnetic Resonance Imaging

Volumn 29, Issue 4, 2009, Pages 887-894

  Chrysochou, Constantina ^a,c   Buckley, David L ^b   Dark, Paul ^a   Cowie, Alistair ^a   Kalra, Philip A ^a  

^a HOPE HOSPITAL   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c Salford Royal Hospital   (United Kingdom)

Author keywords

ASTRAL; Atheromatous renovascular disease; Gadolinium; Nephrogenic systemic fibrosis; NSF

Indexed keywords

ERYTHROPOIETIN; GADODIAMIDE; GADOFOSVESET; GADOLINIUM PENTETATE; IMATINIB; STEROID; THALIDOMIDE;

ARTICLE; CHRONIC KIDNEY DISEASE; CONTRAST ENHANCEMENT; DISEASE COURSE; DRUG BINDING; DRUG BIOAVAILABILITY; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG EXCRETION; DRUG HALF LIFE; DRUG MEGADOSE; DRUG STABILITY; DRUG WITHDRAWAL; FOLLOW UP; HEART RIGHT VENTRICLE DYSPLASIA; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FAILURE; KIDNEY GRAFT; MAGNETIC RESONANCE ANGIOGRAPHY; NEPHROGENIC SYSTEMIC FIBROSIS; PATIENT COMPLIANCE; PLASMAPHERESIS; PRIORITY JOURNAL; PROGNOSIS; PUVA; RECOMMENDED DRUG DOSE; RENAL REPLACEMENT THERAPY; REPEATED DRUG DOSE;

CONTRAST MEDIA; GADOLINIUM; GLOMERULAR FILTRATION RATE; GREAT BRITAIN; HUMANS; KIDNEY DISEASES; LIVER DISEASES; MAGNETIC RESONANCE ANGIOGRAPHY; NEPHROGENIC FIBROSING DERMOPATHY; PROGNOSIS;

EID: 65249177809     PISSN: 10531807     EISSN: 15222586     Source Type: Journal    
DOI: 10.1002/jmri.21708     Document Type: Article

References (63)

1. The Royal College of Radiologists. Gadolinium-based Contrast Media and Nephrogenic Systemic Fibrosis. London: The Royal College
2. of Radiologists, 2007. Ref No. BFCR (07)14 © The Royal College of Radiologists, November 2007. Available at http://www.rcr.ac.uk/docs/radiology/ pdf/BFCR0714-Gadolinium-NSF-guidanceNov07.pdf. Last accessed July 21, 2008. 2007.
3. van den Dool SW, Wasser MN, de Fijter JW, et al. Functional renal volume: quantitative analysis at gadolinium-enhanced MR angiog- raphy-feasibility study in healthy potential kidney donors. Radiology 2005;236:189-195.
4. Bakker J, Olree M, Kaatee R, et al. Renal volume measurements: accuracy and repeatability of US compared with that of MR imaging. Radiology 1999;211:623-628.
5. Coulam CH, Bouley DM, Sommer FG. Measurement of renal volumes with contrast-enhanced MRI. J Magn Reson Imaging 2002; 15:174-179.
6. Kalra PA, Guo H, Kausz AT, et al. Atherosclerotic renovascular disease in United States patients aged 67 years or older: risk factors, revascularization, and prognosis. Kidney Int 2005;68:293- 301.
7. Guo H, Kalra PA, Gilbertson DT, et al. Atherosclerotic renovascular disease in older US patients starting dialysis, 1996 to 2001. Circulation 2007;115:50-58.
8. Conlon PJ, Athirakul K, Kovalik E, et al. Survival in renal vascular disease. J Am Soc Nephrol 1998;9:252-256.
9. Cheung CM, Shurrab AE, Buckley DL, et al. MR-derived renal morphology and renal function in patients with atherosclerotic renovascular disease. Kidney Int 2006;69:715-722.
10. Gandy SJ, Armoogum K, Nicholas RS, et al. A clinical MRI investigation of the relationship between kidney volume measurements and renal function in patients with renovascular disease. Br J Radiol 2007;80:12-20.
11. Mistry S, Ives N, Harding J, et al. Angioplasty and STent for Renal Artery Lesions (ASTRAL trial): rationale, methods and results so far. J Hum Hypertens 2007;21:511-515.
12. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002;39:S1-266.
13. Grobner T. Gadolinium-a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? Nephrol Dial Transplant 2006;21:1104-1108.
14. Marckmann P, Skov L, Rossen K, et al. Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast- enhanced magnetic resonance imaging. J Am Soc Nephrol 2006; 17:2359-2362.
15. Deo A, Fogel M, Cowper SE. Nephrogenic systemic fibrosis: a population study examining the relationship of disease development to gadolinium exposure. Clin J Am Soc Nephrol 2007;2:264-267.
16. Cowper SE, Robin HS, Steinberg SM, et al. Scleromyxoedema-like cutaneous diseases in renal-dialysis patients. Lancet 2000;356: 1000-1001.
17. Cowper SE. Nephrogenic Fibrosing Dermopathy [NFD/NSF Website]. 2001-2007. Available at http://www.icnfdr.org. Last accessed July 21, 2008. 20-1-2008.
18. Evenepoel P, Zeegers M, Segaert S, et al. Nephrogenic fibrosing dermopathy: a novel, disabling disorder in patients with renal failure. Nephrol Dial Transplant 2004;19:469-473.
19. Moreno-Romero JA, Segura S, Mascaro JM Jr, et al. Nephrogenic systemic fibrosis: a case series suggesting gadolinium as a possible aetiological factor. Br J Dermatol 2007;157:783-787.
20. Mendoza FA, Artlett CM, Sandorfi N, et al. Description of 12 cases of nephrogenic fibrosing dermopathy and review of the literature. Semin Arthritis Rheum 2006;35:238-249.
21. Pryor JG, Poggioli G, Galaria N, et al. Nephrogenic systemic fibro- sis: a clinicopathologic study of six cases. J Am Acad Dermatol 2007;57:105-111.
22. Sadowski EA, Bennett LK, Chan MR, et al. Nephrogenic systemic fibrosis: risk factors and incidence estimation. Radiology 2007; 243:148-157.
23. Broome DR, Girguis MS, Baron PW, et al. Gadodiamide-associated nephrogenic systemic fibrosis: why radiologists should be concerned. AJR Am J Roentgenol 2007;188:586-592.
24. Khurana A, Runge VM, Narayanan M, et al. Nephrogenic systemic fibrosis: a review of 6 cases temporally related to gadodiamide injection (Omniscan). Invest Radiol 2007;42:139-145.
25. Collidge TA, Thomson PC, Mark PB, et al. Gadolinium-enhanced MR imaging and nephrogenic systemic fibrosis: retrospective study of a renal replacement therapy cohort. Radiology 2007;245:168- 175.
26. Lim YL, Lee HY, Low SC, et al. Possible role of gadolinium in nephrogenic systemic fibrosis: report of two cases and review of the literature. Clin Exp Dermatol 2007;32:353-358.
27. Runge VM. Safety of approved MR contrast media for intravenous injection. J Magn Reson Imaging 2000;12:205-213.
28. Joffe P, Thomsen HS, Meusel M. Pharmacokinetics of gadodiamide injection in patients with severe renal insufficiency and patients undergoing hemodialysis or continuous ambulatory peritoneal dialysis. Acad Radiol 1998;5:491-502.
29. Boyd AS, Zic JA, Abraham JL. Gadolinium deposition in nephrogenic fibrosing dermopathy. J Am Acad Dermatol 2007;56:27-30.
30. Desreux JF GD. Chemical synthesis of paramagnetic complexes. In: Thomsen HS, Muller RN, Mattrey, editors. Trends in contrast media. Heidelberg: Springer; 2007.
31. Idee JM, Port M, Medina C, et al. Possible involvement of gadolinium chelates in the pathophysiology of nephrogenic systemic fibrosis: a critical review. Toxicology 2008;248:77-88.
32. Quan TE, Cowper SE, Bucala R. The role of circulating fibrocytes in fibrosis. Curr Rheumatol Rep 2006;8:145-150.
33. Cowper SE. Nephrogenic fibrosing dermopathy: the first 6 years. Curr Opin Rheumatol 2003;15:785-790.
34. Cowper SE, Bucala R, LeBoit PE. Nephrogenic fibrosing dermopa- thy/nephrogenic systemic fibrosis-setting the record straight. Se min Arthritis Rheum 2006;35:208-210.
35. High WA, Ayers RA, Chandler J, et al. Gadolinium is detectable within the tissue of patients with nephrogenic systemic fibrosis. J Am Acad Dermatol 2007;56:21-26.
36. High WA, Ayers RA, Cowper SE. Gadolinium is quantifiable within the tissue of patients with nephrogenic systemic fibrosis. J Am Acad Dermatol 2007;56:710-712.
37. Schmidt M, Sun G, Stacey MA, et al. Identification of circulating fibrocytes as precursors of bronchial myofibroblasts in asthma. J Immunol 2003;171:380-389.
38. Jimenez SA, Artlett CM, Sandorfi N, et al. Dialysis-associated systemic fibrosis (nephrogenic fibrosing dermopathy): study of inflammatory cells and transforming growth factor beta1 expression in affected skin. Arthritis Rheum 2004;50:2660-2666.
39. Swartz RD, Crofford LJ, Phan SH, et al. Nephrogenic fibrosing dermopathy: a novel cutaneous fibrosing disorder in patients with renal failure. Am J Med 2003;114:563-572.
40. Shabana WM, Cohan RH, Ellis JH, et al. Nephrogenic systemic fibrosis: a report of 29 cases. AJR Am J Roentgenol 2008;190:736- 741.
41. Othersen JB, Maize JC, Woolson RF, et al. Nephrogenic systemic fibrosis after exposure to gadolinium in patients with renal failure. Nephrol Dial Transplant 2007;22:3179-3185.
42. Swan SK, Lambrecht LJ, Townsend R, et al. Safety and pharmaco- kinetic profile of gadobenate dimeglumine in subjects with renal impairment. Invest Radiol 1999;34:443-448.
43. Saab G, bu-Alfa A. Are patients with moderate renal failure at risk for developing nephrogenic systemic fibrosis? Radiology 2007;244: 930-931.
44. Deo A, Fogel M, Cowper SE. Nephrogenic systemic fibrosis: a population study examining the relationship ofdisease development to gadolinium exposure. Clin J Am Soc Nephrol 2007;2:264-267.
45. Stenver DI. Investigation of the safety of MRI contrast medium Omniscan. Danish Medicines Agency. Available at http://www.dkma.dk/1024/visUKLSArtikel. asp?artikelID=8931. Last accessed April 1, 2008. 29-5-2006.
46. Panda S, Bandyopadhyay D, Tarafder A. Nephrogenic fibrosing dermopathy: a series in a non-Western population. J Am Acad Dermatol 2006;54:155-159.
47. Marckmann P, Skov L, Rossen K, et al. Case-control study of gadodiamide-related nephrogenic systemic fibrosis. Nephrol Dial Transplant 2007;22:3174-3178.
48. Wahba IM, Simpson EL, White K. Gadolinium is not the only trigger for nephrogenic systemic fibrosis: insights from two cases and review of the recent literature. Am J Transplant 2007;7:2425- 2432.
49. Weiss AS, Lucia MS, Teitelbaum I. A case of nephrogenic fibrosing dermopathy/nephrogenic systemic fibrosis. Nat Clin Pract Nephrol 2007;3:111-115.
50. Goveia M CBPP. Evaluating the role of recombinant erythropoietin in nephrogenic systemic fibrosis. J Am Acad Dermatol 2007;725- 727.
51. Swaminathan S, Horn TD, Pellowski D, et al. Nephrogenic systemic fibrosis, gadolinium, and iron mobilization. N Engl J Med 2007; 357:720-722.
52. Abraham JL, Thakral C, Skov L, et al. Dermal inorganic gadolinium concentrations: evidence for in vivo transmet allation and long-term persistence in nephrogenic systemic fibrosis. Br J Dermatol 2008; 158:273-280.
53. Kay J, High WA. Imatinib mesylate treatment of nephrogenic systemic fibrosis. Arthritis Rheum 2008;58:2543-2548.
54. LeBoit PE. What nephrogenic fibrosing dermopathy might be. Arch Dermatol 2003;139:928-930.
55. Maloo M, Abt P, Kashyap R, et al. Nephrogenic systemic fibrosis among liver transplant recipients: a single institution experience and topic update. Am J Transplant 2006;6:2212-2217.
56. Perazella MA, Rodby RA. Gadolinium use in patients with kidney disease: a cause for concern. Semin Dial 2007;20:179-185.
57. Swaminathan S, Shah SV. New insights into nephrogenic systemic fibrosis. J Am Soc Nephrol 2007;18:2636-2343.
58. Prince MR, Zhang H, Morris M, et al. Incidence of nephrogenic systemic fibrosis at two large medical centers. Radiology 2008;248: 807-816.
59. European Congress of Radiology March 2008, Vienna. Available at http://www.dimag.com/ecr2008/showArticle.jhtml?articleID=206902509&cid=D. Last accessed July 21, 2008. 2008.
60. Reilly RF. Risk for nephrogenic systemic fibrosis with gadoteridol (ProHance) in patients who are on long-term hemodialysis. Clin J Am Soc Nephrol 2008;3:747-751.
61. Hedley AJ, Molan MP, Hare DL, et al. Nephrogenic systemic fibrosis associated with gadolinium-containing contrast media administration in patients with reduced glomerular filtration rate. Nephrology (Carlton) 2007;12:111.
62. Weiss AS, Lucia MS, Teitelbaum I. A case of nephrogenic fibrosing dermopathy/nephrogenic systemic fibrosis. Nat Clin Pract Nephrol 2007;3:111-115.
63. Wahba IM, Simpson EL, White K. Gadolinium is not the only trigger for nephrogenic systemic fibrosis: insights from two cases and review of the recent literature. Am J Transplant 2007;7:2425- 2432.